CLEO Diagnostics Advances Ovarian Cancer Test

CLEO Diagnostics Ltd (AU:COV) has released an update.

CLEO Diagnostics Ltd is advancing its novel ovarian cancer detection blood test, starting FDA regulatory processes and initiating U.S. clinical trials with 500 patients to validate the test’s effectiveness. A recent study published in ‘Cancers’ shows the test outperforming current standards, correctly identifying 90% of early-stage cancers. With A$9.373M in cash, the company is also working on market access and reimbursement strategies to ensure early revenue post-regulatory approval.

For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.